Sage depressed by Waterfall
The data were statistically significant, but the market had been hoping for more.
Nightstar becomes nightmare, but Biogen has bigger fish to fry
A second clinical failure means that Biogen threw away $877m, but this sum will today be seen as little more than a rounding error.
Medtech
Aduhelm approval amplifies amyloid assays
Biogen needs blood tests for amyloid beta to progress quickly – and several are in the pipeline.
Medtronic bows to the inevitable
Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
Company Events
Arcus nears crunch time for Gilead opt-in
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Validation for a drug class, and for Sanofi
If imminent results of Sanofi’s amcenestrant in Ameera-3 are positive Serds could finally see late-stage validation.
Interviews
Mitsubishi's Medicago readies for the second wave
Awaiting crucial pivotal data, company reckons its plant-generated Covid-19 vaccine can still make a contribution to the pandemic.
The future of renal denervation
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
Kizoo aims to cure ageing
The German tech investor Kizoo Ventures is committing €300m of its own cash to biotech start-ups working on rejuvenation and healthy lifespan expansion.